# Comparison of Ibandronate - Zoledronate Regarding Nephrotoxicity in Multiple Myeloma

Source: https://onco.cc/trials/nct02739594/  
OnCo record `nct02739594` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Ibandronic acid and Zoledronic acid in Multiple myeloma, run by Hoffmann-La Roche, recorded as terminated on the registry.

## Summary

Comparison of Ibandronate - Zoledronate Regarding Nephrotoxicity in Multiple Myeloma is a phase 3 interventional study registered as NCT02739594 by Hoffmann-La Roche, with 89 participants recorded, started 2006-02 and due to reach its primary completion in 2009-04. Interventions recorded: Ibandronate, Zoledronate. Conditions recorded: Multiple Myeloma.

Linked to the drug Ibandronic acid because the registry names it among its interventions and Multiple myeloma among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT02739594
- Phase: 3
- Setting: COMPARE: Comparison of Ibandronate - Zoledronate Regarding Nephrotoxicity in Patients With Multiple Myeloma
- Sponsor: Hoffmann-La Roche
- Enrolled: 89

## Sources

- ClinicalTrials.gov NCT02739594: https://clinicaltrials.gov/study/NCT02739594

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- drugs: [Ibandronic acid](https://onco.cc/drugs/ibandronic-acid/), [Zoledronic acid](https://onco.cc/drugs/zoledronic-acid/)

---
JSON: https://onco.cc/api/v1/entities/nct02739594.json